Ziten-M 1000mg/20mg Tablet ER is a combination oral antidiabetic medication containing Metformin hydrochloride 1000mg and Teneligliptin 20mg, formulated for extended release. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby effectively lowering blood glucose levels in patients with type 2 diabetes mellitus. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic control. The extended-release formulation allows for once-daily dosing, promoting better patient compliance and stable plasma drug concentrations. Ziten-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when monotherapy with either agent is insufficient. It should be used cautiously in patients with renal impairment and contraindicated in those with severe renal dysfunction, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances and hypoglycemia when used with other antidiabetic agents. Regular monitoring of blood glucose, renal function, and adherence to lifestyle modifications is recommended during therapy with Ziten-M 1000mg/20mg Tablet ER.